Adeno-associated viruses (AAVs) are used in nearly a dozen FDA-approved therapies and more than 900 R&D projects to deliver therapeutic payloads to cells. Yet, large-scale AAV production is still a ...
Efficient viral vector production is essential for the cost-effective manufacture of cell and gene therapies. Many of the current production workflows are reliant on basal media in batch-mode, which ...
Researchers from MIT have developed a bioreactor simulator to predict adeno-associated virus (AAV) yields for insect cell/baculovirus manufacturing. Francesco Destro, PhD, a postdoctoral associate ...
AAVone ® 2.1 has achieved ~1x10 16 genome copies (GC)/L of cell culture and greater than 70% full capsids at harvest, representing a significant advance over AAVone ® 1.0 and conventional ...
Ajinomoto CELLiST Korea, a subsidiary of the Ajinomoto Group specializing in the development and manufacturing of cell culture media, has launched CELLiSTTM AAV Production Supplement 1, a newly ...
Agathos records first sale of recombinant adeno-associated virus produced using AE1-BHK to collaborator Genovac; provides free access to AE1-BHK cell line FARGO, N.D.--(BUSINESS WIRE)--Agathos ...
insights from industryDr Chelsea PrattBiopharma Segment Marketing ManagerBio-Rad Laboratories In this interview, NewsMedical speaks to Dr Chelsea Pratt about Accurately quantifying AAV capsids ...
Virica Biotech ("Virica"), a cell enhancer company specializing in Viral Sensitizers (VSE ™) for viral vector manufacturing, today announced it is receiving advisory services and funding from the ...
Safe and effective gene therapy strategies depend on robust and reliable adeno-associated virus (AAV) mediated therapeutic gene delivery. However, scaling up AAV manufacturing to obtain sufficient ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results